Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VY-AADC01

Gene therapy · developed by Neurocrine Biosciences

Phase 1 Most advanced trial (none active)
1 Registered trials

What is VY-AADC01?

VY-AADC01 is a gene therapy delivered by neurosurgical infusion bilaterally into the striatum. It is studied in Parkinson's disease, a neurodegenerative movement disorder of the basal ganglia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Therapy area
Neurology
Developer
Neurocrine Biosciences
In trials of
VYGR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03065192 Phase 1 Idiopathic Parkinson's Disease Completed VYGR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Basal Ganglia DiseaseBrain DiseasesCentral Nervous System DiseasesIdiopathic Parkinson's DiseaseMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinson's DiseaseParkinsonian Disorders

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.